Premium
Preparation and Stability Evaluation of Size‐Controllable PDHCA ‐ β ‐ CD Nanoparticles as Drug Carrier
Author(s) -
Chu Hong,
Zhao Xue,
Liu Shirong,
Ni Zhongbin,
Shi Dongjian,
Chen Mingqing
Publication year - 2017
Publication title -
chinese journal of chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.28
H-Index - 41
eISSN - 1614-7065
pISSN - 1001-604X
DOI - 10.1002/cjoc.201600867
Subject(s) - chemistry , nanoparticle , dynamic light scattering , polymer , particle size , solvent , drug carrier , nuclear chemistry , chemical engineering , drug delivery , cyclodextrin , amphiphile , polymer chemistry , nanotechnology , copolymer , organic chemistry , materials science , engineering
A novel biocompatible polymer was prepared by grafting the derivate of β ‐cyclodextrin (6‐ SH ‐ β ‐ CD ) onto poly(3,4‐dihydroxycinnamic acid) ( PDHCA ) via Michael addition. PDHCA ‐ β ‐ CD nanoparticles were prepared by the self‐assembly of amphiphilic PDHCA ‐ β ‐ CD polymer with N,N ‐dimethylformamide ( DMF ) as good solvent and water as poor solvent. The PDHCA ‐ β ‐ CD nanoparticles were monodispersed with spherical morphology as shown in the scanning electron microscopic ( SEM ) images in accord with the result of dynamic light scattering ( DLS ) measurement. The size of the nanoparticles could be controlled from 60 to 180 nm by tuning the grafting degree ( GD ) of PDHCA ‐ β ‐ CD polymer and also significantly influenced by the amount of water used during the process. These as‐prepared nanoparticles were stable without any significant change in the particle size after six‐months’ storage and even after being irradiated by UV at λ >280 nm for hours. The formation mechanism of PDHCA ‐ β ‐ CD nanoparticles was explored. The content of doxorubicin ( DOX ) loaded onto the nanoparticles was up to 39% with relatively high loading efficiency (approximately 78.8% of initial DOX introduced was loaded). In vitro release studies suggested that DOX released slowly from PDHCA ‐ β ‐ CD nanoparticles. These features strongly support the potential of developing PDHCA ‐ β ‐ CD nanoparticles as carriers for the controlled delivery of drug.